Lingual-Facial-Buccal Dyskinesia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LNG015 MIFTS: 44	Lingual-Facial-Buccal Dyskinesia Categories: Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lingual-Facial-Buccal Dyskinesia

MalaCards integrated aliases for Lingual-Facial-Buccal Dyskinesia:

Name: Lingual-Facial-Buccal Dyskinesia ¹¹ ¹⁴ ⁷¹

Orofacial Dyskinesia ²⁸ ⁵

Oro-Facial Dyskinesia ¹¹

Dyskinesias ⁴³

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the nervous system

Extrapyramidal and movement disorders

Dystonia

Idiopathic orofacial dystonia

External Ids:

Disease Ontology ¹¹ DOID:9854

ICD9CM ³⁴ 333.82

MeSH ⁴³ D020820

SNOMED-CT ⁶⁸ 267689009

ICD10 ³¹ G24.4

UMLS ⁷¹ C0152115

Sources

Summaries for Lingual-Facial-Buccal Dyskinesia

MalaCards based summary: Lingual-Facial-Buccal Dyskinesia, also known as orofacial dyskinesia, is related to episodic ataxia and parkinson disease, late-onset, and has symptoms including spasmodic torticollis An important gene associated with Lingual-Facial-Buccal Dyskinesia is VPS13A (Vacuolar Protein Sorting 13 Homolog A), and among its related pathways/superpathways are Dopamine-DARPP32 Feedback onto cAMP Pathway and Monoamine GPCRs. The drugs Aripiprazole and Varenicline have been mentioned in the context of this disorder. Affiliated tissues include subthalamic nucleus, lung and brain, and related phenotypes are nervous system and growth/size/body region

Sources

Related Diseases for Lingual-Facial-Buccal Dyskinesia

Diseases related to Lingual-Facial-Buccal Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)

#	Related Disease	Score	Top Affiliating Genes
1	episodic ataxia	30.3	LGI1 FGF14 CNTNAP2
2	parkinson disease, late-onset	30.2	SLC6A3 SLC18A2 HTR2C GRIN2B DRD3 DRD2
3	viral encephalitis	30.2	PNMA2 LGI1 CNTNAP2
4	basal ganglia disease	30.0	XPR1 SLC20A2 MYORG
5	stuttering	30.0	SLC6A3 DRD2 CNTNAP2
6	amnestic disorder	29.9	LGI1 GRIN2B CNTNAP2
7	tic disorder	29.9	SLC6A3 SLC18A2 DRD3 DRD2 CNTNAP2
8	neuroacanthocytosis	29.7	VPS13A PANK2 KEL
9	chronic tic disorder	29.7	SLC18A2 DRD2 CNTNAP2
10	choreoacanthocytosis	29.7	VPS13A PANK2 KEL
11	benign epilepsy with centrotemporal spikes	29.7	LGI1 GRIN2B GRIN1 CNTNAP2
12	pathological gambling	29.7	SLC6A3 DRD3 DRD2
13	post-traumatic stress disorder	29.7	SLC6A3 GRIN2B DRD2
14	huntington disease	29.7	VPS13A SLC6A3 GRIN2B GRIN1 DRD2
15	migraine with or without aura 1	29.7	SLC6A3 HTR2C GRIN2B DRD3 DRD2
16	bulimia nervosa	29.7	SLC6A3 HTR2C DRD2
17	alcohol use disorder	29.6	SLC6A3 GRIN2B DRD3 DRD2
18	toxic encephalopathy	29.6	SLC6A3 SLC18A2 GRIN2B
19	autism	29.5	SLC6A3 GRIN2B GRIN1 FGF14 DRD3 DRD2
20	speech and communication disorders	29.5	SLC6A3 LGI1 GRIN2B CNTNAP2
21	oromandibular dystonia	29.4	VPS13A PANK2
22	gilles de la tourette syndrome	29.4	SLC6A3 SLC18A2 DRD3 DRD2 CNTNAP2
23	cerebellar disease	29.4	FGF14 DPYSL5 CNTNAP2
24	focal dystonia	29.3	SLC6A3 PANK2 DRD2
25	cocaine abuse	29.2	SLC6A3 SLC18A2 DRD3 DRD2
26	impulse control disorder	29.2	SLC6A3 SLC18A2 GRIN2B DRD3 DRD2
27	supranuclear palsy, progressive, 1	29.2	SLC6A3 SLC18A2 IGLON5 DRD2
28	obsessive-compulsive disorder	29.2	SLC6A3 HTR2C GRIN2B DRD3 DRD2 CNTNAP2
29	limbic encephalitis	29.1	PNMA2 LGI1 IGLON5 GRIN2B DPYSL5 CNTNAP2
30	speech disorder	29.1	SLC6A3 LGI1 GRIN2B GRIN1 DRD2 CNTNAP2
31	anxiety	29.1	SLC6A3 HTR2C GRIN2B DRD3 DRD2
32	autism spectrum disorder	29.0	SLC6A3 GRIN2B DRD3 DRD2 CNTNAP2
33	attention deficit-hyperactivity disorder	29.0	SLC6A3 SLC18A2 HTR2C GRIN2B DRD3 DRD2
34	psychotic disorder	29.0	SLC6A3 SLC18A2 HTR2C GRIN2B GRIN1 DRD3
35	mutism	28.9	SLC6A3 PNMA2 LGI1 IGLON5 GRIN1 DPYSL5
36	schizophrenia	28.8	SLC6A3 SLC18A2 HTR2C GRIN2B GRIN1 DRD3
37	alcohol dependence	28.8	SLC6A3 SLC18A2 HTR2C GRIN2B GRIN1 DRD3
38	movement disease	28.7	VPS13A SLC6A3 SLC18A2 PANK2 LGI1 IGLON5
39	bipolar disorder	28.6	SLC6A3 SLC18A2 HTR2C GRIN2B GRIN1 DRD3
40	parkinsonism	28.5	XPR1 SLC6A3 SLC20A2 SLC18A2 PANK2 MYORG
41	dystonia	28.2	XPR1 VPS13A SLC6A3 SLC20A2 SLC18A2 PANK2
42	choreatic disease	27.5	VPS13A SLC6A3 SLC20A2 SLC18A2 PNMA2 PANK2
43	tardive dyskinesia	11.5
44	paroxysmal dyskinesia	11.3
45	dyskinesia, limb and orofacial, infantile-onset	11.3
46	dyskinesia with orofacial involvement, autosomal recessive	11.2
47	dystonia 31	11.2
48	spinocerebellar ataxia 27	11.1
49	myopathy with extrapyramidal signs	11.1
50	neurodevelopmental disorder with hyperkinetic movements and dyskinesia	11.1

Graphical network of the top 20 diseases related to Lingual-Facial-Buccal Dyskinesia:

Sources

Symptoms & Phenotypes for Lingual-Facial-Buccal Dyskinesia

UMLS symptoms related to Lingual-Facial-Buccal Dyskinesia:

spasmodic torticollis

MGI Mouse Phenotypes related to Lingual-Facial-Buccal Dyskinesia:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.2	CNTNAP2 DPYSL5 DRD2 DRD3 FGF14 GRIN1
2	growth/size/body region	MP:0005378	9.97	CNTNAP2 DRD2 DRD3 FGF14 GRIN1 GRIN2B
3	behavior/neurological	MP:0005386	9.83	CNTNAP2 DPYSL5 DRD2 DRD3 FGF14 GRIN1
4	muscle	MP:0005369	9.8	DRD2 FGF14 HTR2C KEL PANK2 SLC18A2
5	taste/olfaction	MP:0005394	9.02	CNTNAP2 DRD2 GRIN1 SLC18A2 SLC6A3

Sources

Drugs & Therapeutics for Lingual-Facial-Buccal Dyskinesia

Drugs for Lingual-Facial-Buccal Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Aripiprazole

Approved, Investigational

Phase 4

129722-12-9

60795

Varenicline

Approved, Investigational

Phase 4

249296-44-4

5310966

Levetiracetam

Approved

Phase 4

102767-28-2

441341 5284583

Carbidopa

Approved

Phase 4

28860-95-9

34359 38101

Amisulpride

Approved, Investigational

Phase 4

71675-85-9, 53583-79-2

2159

Olanzapine

Approved, Investigational

Phase 4

132539-06-1

135398745 4585

Galantamine

Approved

Phase 4

357-70-0, 1953-04-4

9651

Risperidone

Approved, Investigational

Phase 4

106266-06-2

5073

Zonisamide

Approved, Investigational

Phase 4

68291-97-4

5734

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Nicotinic Agonists

Phase 4

Psychotropic Drugs

Phase 4

Antipsychotic Agents

Phase 4

Aromatic Amino Acid Decarboxylase Inhibitors

Phase 4

Nootropic Agents

Phase 4

Dopamine Antagonists

Phase 4

Antidepressive Agents

Phase 4

Gastrointestinal Agents

Phase 4

Omega 3 Fatty Acid

Phase 4

Antiemetics

Phase 4

Serotonin Uptake Inhibitors

Phase 4

Cholinesterase Inhibitors

Phase 4

calcium channel blockers

Phase 4

abobotulinumtoxinA

Phase 4

Botulinum Toxins, Type A

Phase 4

Botulinum Toxins

Phase 4

Cholinergic Agents

Phase 4

Serotonin

Investigational, Nutraceutical

Phase 4

50-67-9

5202

Buspirone

Approved, Investigational

Phase 3

36505-84-7

2477

Amantadine

Approved

Phase 3

768-94-5

2130

Ropinirole

Approved, Investigational

Phase 3

91374-21-9

5095

Tetrabenazine

Approved, Investigational

Phase 3

58-46-8

6018

Piracetam

Approved, Investigational

Phase 3

7491-74-9

4843

Anti-Anxiety Agents

Phase 3

Carbidopa, levodopa drug combination

Phase 3

Analgesics

Phase 3

Adjuvants, Immunologic

Phase 3

Immunologic Factors

Phase 3

Antiviral Agents

Phase 3

Anti-Infective Agents

Phase 3

Analgesics, Non-Narcotic

Phase 3

Cardiac Glycosides

Phase 3

Ginkgo

Phase 3

Neuroprotective Agents

Phase 3

Phenylephrine

Approved

Phase 2

59-42-7

6041

Oxymetazoline

Approved, Investigational

Phase 2

1491-59-4

4636

Amitriptyline

Approved

Phase 2

50-48-6

2160

Pimavanserin

Approved, Investigational

Phase 2

706779-91-1

10071196

Entacapone

Approved, Investigational

Phase 2

130929-57-6

5281081

Nicotine

Approved

Phase 1, Phase 2

54-11-5

942 89594

Interventional clinical trials:

(show top 50) (show all 239)

#	Name	Status	NCT ID	Phase	Drugs
1	Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study	Unknown status	NCT00837707	Phase 4	aripiprazole
2	The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial	Unknown status	NCT00468533	Phase 4	Aripiprazole
3	Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response	Unknown status	NCT03495024	Phase 4	Varenicline
4	Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics	Completed	NCT00888186	Phase 4	levodopa/carbidopa
5	Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study	Completed	NCT00307450	Phase 4	Levetiracetam
6	A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia	Completed	NCT03891862	Phase 4	Valbenazine;Placebo oral capsule
7	A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine	Completed	NCT03698331	Phase 4	Valbenazine;Placebo oral capsule
8	A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia	Completed	NCT00114595	Phase 4	eicosapentaenoic acid
9	Tardive Dyskinesia and Cognitive Function	Completed	NCT00926965	Phase 4	amisulpride;Olanzapine;Conventional antipsychotics
10	Treatment of Tardive Dyskinesia With Galantamine	Completed	NCT00164242	Phase 4	Galantamine
11	Validation of Dyskinesia Rating Scales	Completed	NCT01071395	Phase 4	Amantadine;Placebo
12	A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia	Completed	NCT00621998	Phase 4	risperidone;olanzapine
13	An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease	Suspended	NCT03034538	Phase 4	Zonegran
14	Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study	Terminated	NCT00477802	Phase 4
15	Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial	Unknown status	NCT02617017	Phase 3	Buspirone;Placebo
16	Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease	Unknown status	NCT00260793	Phase 3	Ropinirole Hydrochloride
17	A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.	Completed	NCT00363727	Phase 3	ropinirole controlled-release (REQUIP CR) for RLS
18	Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects	Completed	NCT00360568	Phase 3	Levodopa-carbidopa intestinal gel
19	A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia	Completed	NCT00672373	Phase 3	Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
20	A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia	Completed	NCT02291861	Phase 3	SD-809;Placebo
21	Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia	Completed	NCT02736955	Phase 3	Valbenazine
22	An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)	Completed	NCT02799381	Phase 3	Optimized antiparkinsonian treatment;Levodopa-Carbidopa Intestinal Gel (LCIG)
23	ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)	Completed	NCT02274766	Phase 3	ADS-5102
24	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia	Completed	NCT02274558	Phase 3	NBI-98854;Placebo
25	A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents	Completed	NCT03813238	Phase 3	Deutetrabenazine;Placebo
26	Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)	Completed	NCT02136914	Phase 3	ADS-5102
27	A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia	Completed	NCT00105508	Phase 3	Sarizotan;Placebo
28	A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT)	Completed	NCT03176771	Phase 2, Phase 3	MT-5199;Placebo
29	Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study	Completed	NCT00190008	Phase 3	piracetam
30	A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia	Completed	NCT00105521	Phase 3	Sarizotan;Placebo
31	A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia	Completed	NCT02405091	Phase 3	NBI-98854
32	Levetiracetam Treatment of Tardive Dyskinesia	Completed	NCT00291213	Phase 3	levetiracetam;placebo
33	Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)	Completed	NCT01397422	Phase 2, Phase 3	ADS-5102 (extended release amantadine HCl)
34	Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)	Completed	NCT02202551	Phase 3	ADS-5102
35	An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia	Completed	NCT02198794	Phase 3	SD-809;Placebo
36	A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia	Completed	NCT02195700	Phase 2, Phase 3	SD-809;Placebo
37	Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial	Completed	NCT01543321	Phase 3	Tetrabenazine;Placebo
38	Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy	Recruiting	NCT04857359	Phase 2, Phase 3	Dipraglurant;Placebo
39	An Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy With or Without Concomitant Dopaminergic Medications	Recruiting	NCT05116813	Phase 2, Phase 3	Dipraglurant
40	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy	Recruiting	NCT05206513	Phase 3	Placebo;Valbenazine
41	A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias	Terminated	NCT02153645	Phase 3	240mg Amantadine HCl ER tablets;Placebo tablets;320mg Amantadine HCl ER tablets
42	A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias	Terminated	NCT02153632	Phase 3	amantadine HCl ER;Placebo
43	Pyridoxal Kinase Activity in Schizophrenia Patients Without Versus With Tardive Dyskinesia Treated With Vitamin B6	Withdrawn	NCT01908452	Phase 3	Pyridoxine
44	Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia	Withdrawn	NCT03254186	Phase 2, Phase 3	Propranolol Hydrochloride;Placebo Oral Tablet
45	A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations	Withdrawn	NCT03987750	Phase 3	Safinamide Methanesulfonate 150mg;Safinamide Methanesulfonate 100mg;Safinamide Methanesulfonate matching placebo
46	Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial	Unknown status	NCT00291733	Phase 2	Levetiracetam;Placebo
47	Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Omega-3 Supplementation With Docosahexaenoic Acid (DHA) on Tardive Dyskinesia	Unknown status	NCT00621634	Phase 2
48	Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease	Unknown status	NCT02439125	Phase 2	Eltoprazine HCl;Placebo
49	Randomized Controlled Trial of Laparoscopic Cholecystectomy vs. Non-operative Treatment for Gallbladder Dyskinesia	Unknown status	NCT02195115	Phase 2	amitriptyline
50	A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Severe L-dopa Induced Dyskinesias	Completed	NCT00888004	Phase 2	AFQ056;Placebo

Search NIH Clinical Center for Lingual-Facial-Buccal Dyskinesia

Cochrane evidence based reviews: dyskinesias

Sources

Genetic Tests for Lingual-Facial-Buccal Dyskinesia

Genetic tests related to Lingual-Facial-Buccal Dyskinesia:

#	Genetic test	Affiliating Genes
1	Orofacial Dyskinesia ²⁸

Sources

Anatomical Context for Lingual-Facial-Buccal Dyskinesia

Organs/tissues related to Lingual-Facial-Buccal Dyskinesia:

MalaCards : Subthalamic Nucleus, Lung, Brain, Tongue, Globus Pallidus, Heart, Liver

Sources

Publications for Lingual-Facial-Buccal Dyskinesia

Articles related to Lingual-Facial-Buccal Dyskinesia:

(show top 50) (show all 312)

#	Title	Authors	PMID	Year
1	Movement disorders of the mouth: a review of the common phenomenologies. ⁶²	Ghadery CM...Connolly BS	35904592	2022
2	Orofacial dyskinesia in a patient with autoimmune encephalitis and voltagegated potassium channel complex antibodies ⁶²	Gul Orhan I...Tezer FI	35894674	2022
3	Orofacial dyskinesia with choreoathetoid movements caused by brainstem encephalitis: A rare complication of SARS-CoV-2-related multisystem inflammatory syndrome in children. ⁶²	Sen S...Sinhamahapatra TK	35148008	2022
4	Bilateral Focused Ultrasound Pallidotomy for Parkinson-Related Facial Dyskinesia-A Case Report. ⁶²	Stieglitz LH...Baumann CR	35844284	2022
5	Compound Heterozygous VPS13A Variants in a Patient with Neuroacanthocytosis: A Case Report and Review of the Literature. ⁶²	Kim A...Park HS	35075478	2022
6	Orofacial Dyskinesia and Intractable Hiccups in a Patient with Varicella-Zoster Virus Encephalomyelitis. ⁶²	Funatsu A...Mine H	35676037	2022
7	Understanding and management of anti-N-methyl-D-aspartate receptor encephalitis from a child psychiatry perspective: report of five cases. ⁶²	Dogan N...Serin HM	35672904	2022
8	On the quest for hidden ovarian teratomas in therapy-refractory anti-NMDA receptor encephalitis: a case report. ⁶²	Cirkel C...Machner B	35462557	2022
9	Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones. ⁶²	Mezzomo NF...Peroza LR	34854012	2022
10	A case of QARS1 associated epileptic encephalopathy and review of epilepsy in aminoacyl-tRNA synthetase disorders. ⁶²	Chan DL...Mohammad SS	34774383	2022
11	PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. ⁶²	Sonego AB...Guimaraes FS	34048863	2021
12	Anti-N-methyl-D-aspartate receptor encephalitis: An observational and comparative study in Mexican children and adults. ⁶²	Herrera-Mora P...Cardenas G	34688092	2021
13	Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis in Children and Adolescents: A Systematic Review and Quantitative Analysis of Reported Cases. ⁶²	Giri YR...Hashmi S	34777507	2021
14	Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report. ⁶²	Sakai S...Ozawa H	34357702	2021
15	Long-acting Methylphenidate Induced Transient Orofacial Dyskinesia and Upper Extremity Choreoathetosis: A Case Report. ⁶²	Trombetta D...Anand V	34461003	2021
16	Masked Tardive Dyskinesia in the Coronavirus Disease 2019 Era. ⁶²	Laboe C...Cardiel Sam H	34540401	2021
17	Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia. ⁶²	Wang MH...Soung HS	33523404	2021
18	SLC20A2 mutation manifesting as very late-onset orofacial dyskinesia. ⁶²	Woo KA...Jeon B	33452934	2021
19	Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia. ⁶²	Nagaoka K...Kaneko S	33857021	2021
20	The challenge of diagnosing and successfully treating anti-NMDA receptor encephalitis in a toddler. ⁶²	Alqassmi AA...Salih MA	33879947	2021
21	Effects of CATECHIN on reserpine-induced vacuous chewing movements: behavioral and biochemical analysis. ⁶²	Reinheimer JB...Fachinetto R	32725283	2020
22	Orofacial dyskinesia post resection of pineal gland tumor. ⁶²	Yazbeck M...Comair Y	33391638	2020
23	Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report. ⁶²	Wietholter JP...Piechowski K	32761113	2020
24	Late-onset oro-facial dyskinesia in Spinocerebellar Ataxia type 2: a case report. ⁶²	Giardina F...Ferri R	32340607	2020
25	Combined Dendritic and Axonal Deterioration Are Responsible for Motoneuronopathy in Patient-Derived Neuronal Cell Models of Chorea-Acanthocytosis. ⁶²	Gla? H...Hermann A	32151030	2020
26	Resolution of tardive tremor after bilateral subthalamic nucleus deep brain stimulation placement. ⁶²	Kashyap S...Ananda A	33408929	2020
27	Frontotemporal brain sagging syndrome: Craniospinal hypovolemia secondary to a T6-T7 cerebrospinal fluid-venous fistula. ⁶²	Ortega-Porcayo LA...Zazueta MO	32905237	2020
28	Orofacial Dyskinesia in a Young Man. ⁶²	Tian X...Xiao F	31545336	2019
29	[Acute neuropsychiatry: a confused patient and a puzzled doctor]. ⁶²	Eppinga H...van Zelst WH	32073794	2019
30	Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances. ⁶²	Kronbauer M...Burger ME	31374223	2019
31	Correction to: Novel mutations in KMT2B offer pathophysiological insights on childhood-onset progressive dystonia. ⁶²	Dafsari HS...Cirak S	31388109	2019
32	Novel mutations in KMT2B offer pathophysiological insights into childhood-onset progressive dystonia. ⁶²	Dafsari HS...Cirak S	31165786	2019
33	18F-FDG PET/CT: an unexpected case of Huntington's disease. ⁶²	Michels S...Schreckenberger M	31043171	2019
34	Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. ⁶²	Schirinzi T...Leuzzi V	30642806	2019
35	Anti-N-methyl-d-aspartate receptor encephalitis during pregnancy: A case report. ⁶²	Keskin AO...Ozturk V	30788880	2019
36	Clinical Profile and Neuropsychiatric Outcome in Children with Anti-NMDAR Encephalitis. ⁶²	Nair A V...Kuzhikkathukandiyil P	30955001	2019
37	Severe tooth loss secondary to orofacial dyskinesias in anti-NMDA receptor encephalitis. ⁶²	Di Luca DG...Margolesky JH	30846455	2019
38	A review for the pharmacological effect of lycopene in central nervous system disorders. ⁶²	Chen D...Chen Z	30616078	2019
39	Infectious Trigger for Autoimmune Encephalitis: A Case Report and Literature Review. ⁶²	Sahar N...Simon RQ	31781432	2019
40	Possible nitric oxide mechanism involved in the protective effect of L-theanine on haloperidol-induced orofacial dyskinesia. ⁶²	Tsai CC...Tseng HC	30942195	2019
41	TLE1, a key player in neurogenesis, a new candidate gene for autosomal recessive postnatal microcephaly. ⁶²	Cavallin M...Bahi-Buisson N	29758293	2018
42	Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. ⁶²	Sonego AB...Guimaraes FS	30217539	2018
43	Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy. ⁶²	Arslan EA...Goksu O	28328695	2018
44	Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats. ⁶²	Dhingra D...Gahalain N	28641484	2018
45	L-Theanine Decreases Orofacial Dyskinesia Induced by Reserpine in Rats. ⁶²	Soung HS...Tseng HC	29629512	2018
46	Anti-NMDA receptor encephalitis: still unknown and underdiagnosed by physicians and especially by psychiatrists? ⁶²	Hermans T...Lemmens GMD	29050531	2018
47	Dexmethylphenidate Extended Release-Associated Orofacial Dyskinesia in an Adolescent with Autism Spectrum Disorder After Prolonged Use. ⁶²	Baweja R...Waxmonsky J	29781724	2018
48	Pediatric NMDAR encephalitis: A single center observation study with a closer look at movement disorders. ⁶²	Granata T...Nardocci N	29396169	2018
49	Acute-onset Orofacial Dyskinesia with a Single Low Dose of Oral Flupentixol: A Case Report. ⁶²	Gupta P...Balhara YPS	29962578	2018
50	Protective Effect of L-Theanine on Haloperidol-Induced Orofacial. ⁶²	Chen CN...Soung HS	29374957	2018

Sources

Genes for Lingual-Facial-Buccal Dyskinesia

Genes related to Lingual-Facial-Buccal Dyskinesia (0 elite genes):

(show all 19)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	VPS13A	Vacuolar Protein Sorting 13 Homolog A	Protein Coding	7.36	DISEASES inferred ¹⁴
2	GRIN1	Glutamate Ionotropic Receptor NMDA Type Subunit 1	Protein Coding	6.56	DISEASES inferred ¹⁴
3	LGI1	Leucine Rich Glioma Inactivated 1	Protein Coding	6.3	DISEASES inferred ¹⁴
4	SLC20A2	Solute Carrier Family 20 Member 2	Protein Coding	6.13	DISEASES inferred ¹⁴
5	CNTNAP2	Contactin Associated Protein 2	Protein Coding	5.95	DISEASES inferred ¹⁴
6	SLC6A3	Solute Carrier Family 6 Member 3	Protein Coding	5.9	DISEASES inferred ¹⁴
7	FGF14	Fibroblast Growth Factor 14	Protein Coding	5.85	DISEASES inferred ¹⁴
8	XPR1	Xenotropic And Polytropic Retrovirus Receptor 1	Protein Coding	5.83	DISEASES inferred ¹⁴
9	HTR2C	5-Hydroxytryptamine Receptor 2C	Protein Coding	5.8	DISEASES inferred ¹⁴
10	DRD3	Dopamine Receptor D3	Protein Coding	5.72	DISEASES inferred ¹⁴
11	IGLON5	IgLON Family Member 5	Protein Coding	5.71	DISEASES inferred ¹⁴
12	PNMA2	PNMA Family Member 2	Protein Coding	5.62	DISEASES inferred ¹⁴
13	MYORG	Myogenesis Regulating Glycosidase (Putative)	Protein Coding	5.59	DISEASES inferred ¹⁴
14	DRD2	Dopamine Receptor D2	Protein Coding	5.58	DISEASES inferred ¹⁴
15	DPYSL5	Dihydropyrimidinase Like 5	Protein Coding	5.56	DISEASES inferred ¹⁴
16	KEL	Kell Metallo-Endopeptidase (Kell Blood Group)	Protein Coding	5.53	DISEASES inferred ¹⁴
17	SLC18A2	Solute Carrier Family 18 Member A2	Protein Coding	5.49	DISEASES inferred ¹⁴
18	PANK2	Pantothenate Kinase 2	Protein Coding	5.48	DISEASES inferred ¹⁴
19	GRIN2B	Glutamate Ionotropic Receptor NMDA Type Subunit 2B	Protein Coding	5.4	DISEASES inferred ¹⁴

Sources

Variations for Lingual-Facial-Buccal Dyskinesia

ClinVar genetic disease variations for Lingual-Facial-Buccal Dyskinesia:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	HERC2	NM_004667.6(HERC2):c.5045A>G (p.Asn1682Ser)	SNV	Uncertain Significance	599009	rs140073033	GRCh37: 15:28474681-28474681 GRCh38: 15:28229535-28229535
2	RYR1	NM_000540.3(RYR1):c.1312G>C (p.Glu438Gln)	SNV	Uncertain Significance	599010	rs765668209	GRCh37: 19:38943526-38943526 GRCh38: 19:38452886-38452886

Sources

Expression for Lingual-Facial-Buccal Dyskinesia

Search GEO for disease gene expression data for Lingual-Facial-Buccal Dyskinesia.

Sources

Pathways for Lingual-Facial-Buccal Dyskinesia

Pathways related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Dopamine-DARPP32 Feedback onto cAMP Pathway ⁶⁴	11.81	GRIN2B GRIN1 DRD3 DRD2
2	Monoamine GPCRs ⁷⁴ Show member pathways Adrenaline signalling through Alpha-2 adrenergic receptor ⁶⁶ Adrenoceptors ⁶⁶ Amine ligand-binding receptors ⁶⁶ Histamine receptors ⁶⁶ Muscarinic acetylcholine receptors ⁶⁶ Serotonin receptors ⁶⁶	11.47	HTR2C DRD3 DRD2
3	Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics ⁶⁰ Show member pathways Nicotine effect on dopaminergic neurons ⁷⁴	10.96	SLC18A2 DRD3 DRD2
4	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	10.62	HTR2C DRD2
5	Methylphenidate Pathway, Pharmacodynamics ⁶⁰ Show member pathways Dopamine receptors ⁶⁶	10.29	SLC6A3 SLC18A2 DRD3 DRD2

Sources

GO Terms for Lingual-Facial-Buccal Dyskinesia

Cellular components related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016021	10.35	CNTNAP2 DRD2 DRD3 GRIN1 GRIN2B HTR2C
2	membrane	GO:0016020	10.35	CNTNAP2 DRD2 DRD3 GRIN1 GRIN2B HTR2C
3	plasma membrane	GO:0005887	10.03	DRD2 DRD3 GRIN1 GRIN2B HTR2C SLC18A2
4	plasma membrane	GO:0005886	10.03	DRD2 DRD3 GRIN1 GRIN2B HTR2C SLC18A2
5	postsynaptic membrane	GO:0045211	9.8	SLC6A3 GRIN2B GRIN1 DRD2
6	NMDA selective glutamate receptor complex	GO:0017146	9.56	GRIN2B GRIN1
7	dopaminergic synapse	GO:0098691	9.1	SLC6A3 SLC18A2 DRD2

Biological processes related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show all 29)

#	Name	GO ID	Score	Top Affiliating Genes
1	social behavior	GO:0035176	10.05	VPS13A DRD3 CNTNAP2
2	visual learning	GO:0008542	10.02	GRIN1 DRD3 DRD2
3	cellular calcium ion homeostasis	GO:0006874	10	KEL HTR2C DRD3 DRD2
4	G protein-coupled receptor internalization	GO:0002031	9.94	DRD3 DRD2
5	excitatory chemical synaptic transmission	GO:0098976	9.93	GRIN2B GRIN1
6	negative regulation of synaptic transmission, glutamatergic	GO:0051967	9.92	DRD3 DRD2
7	calcium ion transmembrane import into cytosol	GO:0097553	9.92	GRIN2B GRIN1
8	positive regulation of cysteine-type endopeptidase activity	GO:2001056	9.91	GRIN2B GRIN1
9	negative regulation of cytosolic calcium ion concentration	GO:0051481	9.91	DRD3 DRD2
10	positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway	GO:0051482	9.91	HTR2C DRD3 DRD2
11	monoamine transport	GO:0015844	9.9	SLC6A3 SLC18A2
12	adenohypophysis development	GO:0021984	9.89	DRD2 SLC6A3
13	phospholipase C-activating dopamine receptor signaling pathway	GO:0060158	9.88	DRD2 DRD3
14	response to cocaine	GO:0042220	9.88	SLC6A3 DRD3 DRD2
15	hyaloid vascular plexus regression	GO:1990384	9.87	SLC6A3 DRD2
16	regulation of monoatomic cation transmembrane transport	GO:1904062	9.86	GRIN2B GRIN1
17	dopamine uptake involved in synaptic transmission	GO:0051583	9.84	SLC6A3 DRD2
18	adenylate cyclase-inhibiting dopamine receptor signaling pathway	GO:0007195	9.83	DRD2 DRD3
19	phosphate ion transport	GO:0006817	9.82	XPR1 SLC20A2
20	dopamine transport	GO:0015872	9.81	SLC18A2 SLC6A3
21	regulation of potassium ion transport	GO:0043266	9.8	DRD2 DRD3
22	regulation of dopamine uptake involved in synaptic transmission	GO:0051584	9.78	DRD2 DRD3
23	response to histamine	GO:0034776	9.67	DRD2 DRD3
24	regulation of biological quality	GO:0065008	9.63	DRD3 DRD2
25	prepulse inhibition	GO:0060134	9.63	SLC6A3 DRD3 DRD2
26	acid secretion	GO:0046717	9.62	DRD2 DRD3
27	regulation of locomotion involved in locomotory behavior	GO:0090325	9.56	DRD3 DRD2
28	response to ethanol	GO:0045471	9.56	SLC6A3 GRIN2B GRIN1 DRD3 DRD2
29	locomotory behavior	GO:0007626	9.4	VPS13A SLC6A3 SLC18A2 HTR2C DRD3 DRD2

Molecular functions related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	glutamate binding	GO:0016595	9.71	GRIN2B GRIN1
2	monoamine transmembrane transporter activity	GO:0008504	9.67	SLC6A3 SLC18A2
3	NMDA glutamate receptor activity	GO:0004972	9.62	GRIN2B GRIN1
4	dopamine binding	GO:0035240	9.56	SLC6A3 DRD2
5	glutamate-gated calcium ion channel activity	GO:0022849	9.46	GRIN2B GRIN1
6	dopamine neurotransmitter receptor activity	GO:0004952	8.96	DRD3 DRD2
7	dopamine neurotransmitter receptor activity, coupled via Gi/Go	GO:0001591	8.92	DRD3 DRD2